Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 477 participants.
Also called NCT05120193
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 477 participants
- Registry
-
NCT05120193
-
- Other papers using this trial's data
- Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial
- Impact of linear ablation in persistent atrial fibrillation using a dual-energy, wide-footprint catheter: Analysis from the SPHERE Per-AF randomized trial
- Operator learning curve with a novel dual-energy lattice-tip ablation system
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Israel
- Registry status
- Completed
Technical summary
Registry record NCT05120193. Randomized; single masking; primary purpose treatment. Start 2021-12-14 (actual); primary completion 2024-01-10 (actual). Results posted on 2025-02-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System
- Acronym
- SPHERE Per-AF
- Condition
- Atrial Fibrillation
- Intervention (Device)
- Mapping and Ablation
- Lead sponsor
- Medtronic Cardiac Ablation Solutions
Record details
- Record id
cardio:ct-nct05120193- Content hash
8daad0e2017437979a26afc85c71dddc0ed687653421a18a84752f48d5b54bec